Company intelligence / Profile preview

Iris Acquisition

Dubai, United Arab Emirates

Ownership: Private
Development stage: Other

Overview

Iris Acquisition is a special purpose acquisition company (SPAC) structure used to take other businesses public; it is not itself an operating life science/biotech company. The first SPAC vehicle, Iris Acquisition Corp, completed a business combination with Liminatus Pharma in April 2025, after which the combined operating company is named Liminatus Pharma and trades as LIMN/LIMNW on Nasdaq.[4][5]

Industry: Investors

Beyond the preview

Go deeper on Iris Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iris Acquisition.

Explore the full profile